MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALMS stock logo

ALMS

Alumis Inc. Common Stock

$23.37
0.64
 (2.82%)
Exchange:  NASDAQ
Market Cap:  2.878B
Shares Outstanding:  7.498M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Martin Babler
Full Time Employees:  168
Address: 
280 East Grand Avenue
South San Francisco
CA
94080
US
Website:  https://www.alumis.com
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue0024,050
Gross Profit0-3,15220,554
EBITDA-156,890-297,602-423,708
Operating Income-158,174-300,754-427,204
Net Income-154,993-294,233-243,325

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets89,612340,992411,940
Total Liabilities53,50280,889110,643
Total Stockholders Equity36,110260,103301,297
Total Debt32,58030,72236,914
Cash and Cash Equivalents45,996169,52689,670

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-129,975-255,078-369,523
Capital Expenditure-4,499-1,732-653
Free Cash Flow-134,474-256,810-370,176
Net Income-154,993-294,233-243,325
Net Change in Cash20,293123,499-79,579

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)497,402.117Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,149,126.429Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)840,354.500Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)248,701.058Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)574,563.214Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)420,177.250Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)370,576.107Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,166,402.371Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)789,355.509Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)847,993.051Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,959,081.383Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,432,673.390Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.930Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.370Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.440Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)7Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
127.95
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-10.75
?Enterprise Value
 (TTM)
: 
3.024B  ?EV/FCF
 (TTM)
: 
-8.17
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.73  ?ROIC
 (TTM)
: 
-1.24
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.12
?P/B
 (TTM)
: 
8.68  ?Current Ratio
 (TTM)
: 
4.34

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ALMS Intrinsic Value

Common questions about ALMS valuation

Is Alumis Inc. Common Stock (ALMS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Alumis Inc. Common Stock (ALMS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ALMS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALMS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ALMS’s P/E ratio?

You can see ALMS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ALMS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ALMS a good long-term investment?

Whether ALMS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ALMS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.82
MARKETSnap

Trading Metrics:

Open: 21.96   Previous Close: 22.73
Day Low: 21.62   Day High: 23.89
Year Low: 2.76   Year High: 30.6
Price Avg 50: 26.27   Price Avg 200: 11.54
Volume: 1.404M   Average Volume: 1.481M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
25-03-2026 12:39
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
19-03-2026 16:05
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
09-01-2026 16:05
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Alumis Announces Pricing of Upsized Public Offering of Common Stock
07-01-2026 22:52
Alumis Announces Pricing of Upsized Public Offering of Common Stock
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
07-01-2026 12:56
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
06-01-2026 17:12
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read